Verona Pharma plc Asset Resilience Ratio
Verona Pharma plc asset resilience ratio. Verona Pharma plc (I9SA) has an Asset Resilience Ratio of 0.00% as of September 2020. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See operational self-sufficiency of Verona Pharma plc to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Verona Pharma plc (2017–2019)
Asset resilience ratio of Verona Pharma plc from 2017 to 2019. This chart shows how Verona Pharma plc's Asset Resilience Ratio has changed over time. Read Verona Pharma plc debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Verona Pharma plc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see balance sheet size of Verona Pharma plc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €0.00 | 0% |
| Total Liquid Assets | €0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Verona Pharma plc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Verona Pharma plc Industry Peers by Asset Resilience Ratio
Compare Verona Pharma plc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.76% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
Verona Pharma plc Asset Resilience Ratio by Year (2017–2019)
Verona Pharma plc asset resilience ratio by year from 2017 to 2019. The table below shows the annual Asset Resilience Ratio data for Verona Pharma plc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2019-12-31 | 17.33% | €10.26 Million ≈ $11.99 Million |
€59.18 Million ≈ $69.19 Million |
-43.16pp |
| 2018-12-31 | 60.49% | €57.00 Million ≈ $66.64 Million |
€94.23 Million ≈ $110.17 Million |
+5.94pp |
| 2017-12-31 | 54.54% | €65.97 Million ≈ $77.13 Million |
€120.96 Million ≈ $141.41 Million |
-- |
About Verona Pharma plc
Verona Pharma plc, a biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company offers Ohtuvayre, a dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that combines bronchodilator and non-steroidal anti-inflammatory effects for the maintenance treatment of chronic obstructive pu… Read more